Carfilzomib + Lenalidomide + Dexamethasone for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is the combination of Carfilzomib, Lenalidomide, and Dexamethasone safe for humans?
Carfilzomib has been associated with heart and lung-related side effects, as shown in studies like the ASPIRE and ENDEAVOUR trials. Lenalidomide has a predictable safety profile, but it can cause serious side effects in some patients, such as infections and other non-blood-related issues. It's important to discuss these potential risks with your doctor to understand how they might apply to you.12345
What makes the drug combination of Carfilzomib, Lenalidomide, and Dexamethasone unique for treating multiple myeloma?
This drug combination is unique because it includes Carfilzomib, a proteasome inhibitor that works by blocking the protein complex responsible for breaking down proteins in cells, leading to cancer cell death. It has shown significant improvement in progression-free survival for patients with relapsed multiple myeloma compared to Lenalidomide and Dexamethasone alone, although it did not show superior results for newly diagnosed patients compared to the standard treatment.678910
What data supports the effectiveness of the drug combination Carfilzomib, Lenalidomide, and Dexamethasone for treating multiple myeloma?
Who Is on the Research Team?
Andrzej Jakubowiak, MD, PhD
Principal Investigator
University of Chicago
Are You a Good Fit for This Trial?
Adults over 18 with multiple myeloma who've had a stem-cell transplant can join this trial. They should be in good health, have stable disease post-transplant, and agree to birth control measures if applicable. Exclusions include recent radiation or surgery, certain heart conditions, uncontrolled blood pressure or diabetes, active infections, and known HIV/HBV/HCV infection.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a combination of Carfilzomib, Lenalidomide, and Dexamethasone or Lenalidomide alone after stem-cell transplant
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Carfilzomib
- Dexamethasone
- Lenalidomide
Carfilzomib is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor